Prostate: 中国老年男性良性前列腺增生患者的前列腺形态学参数与临床进展的相关性研究

2021-04-30 AlexYang MedSci原创

最近,有研究人员调查了中国老年男性的前列腺形态学参数与良性前列腺增生(BPH)临床进展的相关性情况。

最近,有研究人员调查了中国老年男性的前列腺形态学参数与良性前列腺增生(BPH)临床进展的相关性情况

研究是一项回顾性研究中,共包括了1038名患者。通过经直肠超声(TRUS)测量了前列腺形态。记录了所有候选人的详细病史,并根据具体的前列腺测量结果进行了分类分析,并采用单变量和多变量的逻辑回归分析评估了变量之间的相关性。

研究结果发现,研究人群中BPH临床进展的累积发生率为63.68%(661/1038)。前列腺体积(PV)、过渡区体积(TZV)、过渡区指数(TZI)和膀胱内前列腺突起(IPP)均与BPH进展呈正相关(所有P<0.001)。PV>60ml、TZV>15ml、TZI>0.5或IPP>5mm的患者,整体BPH临床进展的可能性明显较高(调整后的OR:分别为2.485、1.678、1.886和1.924;95%CI:1.559-3.960、1.131-2.489、1.379-2.579和1.357-2.728)。

BPH临床进展相关因素的单变量分析

最后,研究人员指出,前列腺形态学参数与前列腺增生症的临床进展显著相关。前列腺形态学参数较大的患者更容易出现临床进展。因此,在临床进展发生之前,应及时考虑对这些患者进行合理的治疗。

原始出处:

Subo Qian, Shun Zhang, Weimin Xia et al. Correlation of prostatic morphological parameters and clinical progression in aging Chinese men with benign prostatic hyperplasia: Results from a cross-sectional study. Prostate. Apr 2021

 

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1897867, encodeId=318d189e867a3, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Oct 05 13:20:48 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837930, encodeId=cc01183e9306e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 01 01:20:48 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364724, encodeId=76491364e24e5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509709, encodeId=d1c91509e0935, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602361, encodeId=300c160236172, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1897867, encodeId=318d189e867a3, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Oct 05 13:20:48 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837930, encodeId=cc01183e9306e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 01 01:20:48 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364724, encodeId=76491364e24e5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509709, encodeId=d1c91509e0935, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602361, encodeId=300c160236172, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1897867, encodeId=318d189e867a3, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Oct 05 13:20:48 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837930, encodeId=cc01183e9306e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 01 01:20:48 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364724, encodeId=76491364e24e5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509709, encodeId=d1c91509e0935, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602361, encodeId=300c160236172, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=)]
    2021-05-02 lsndxfj
  4. [GetPortalCommentsPageByObjectIdResponse(id=1897867, encodeId=318d189e867a3, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Oct 05 13:20:48 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837930, encodeId=cc01183e9306e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 01 01:20:48 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364724, encodeId=76491364e24e5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509709, encodeId=d1c91509e0935, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602361, encodeId=300c160236172, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1897867, encodeId=318d189e867a3, content=<a href='/topic/show?id=a3b080193fe' target=_blank style='color:#2F92EE;'>#老年男性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80193, encryptionId=a3b080193fe, topicName=老年男性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=226a143, createdName=cathymary, createdTime=Tue Oct 05 13:20:48 CST 2021, time=2021-10-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1837930, encodeId=cc01183e9306e, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sun Aug 01 01:20:48 CST 2021, time=2021-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1364724, encodeId=76491364e24e5, content=<a href='/topic/show?id=7c5615628ad' target=_blank style='color:#2F92EE;'>#ROS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15628, encryptionId=7c5615628ad, topicName=ROS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=acc3210, createdName=lsndxfj, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1509709, encodeId=d1c91509e0935, content=<a href='/topic/show?id=c96f866535c' target=_blank style='color:#2F92EE;'>#良性前列腺增生#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=86653, encryptionId=c96f866535c, topicName=良性前列腺增生)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a42f10130242, createdName=刘阔, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1602361, encodeId=300c160236172, content=<a href='/topic/show?id=2f801469e57' target=_blank style='color:#2F92EE;'>#PRO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=14697, encryptionId=2f801469e57, topicName=PRO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a60b18898917, createdName=sunylz, createdTime=Sun May 02 14:20:48 CST 2021, time=2021-05-02, status=1, ipAttribution=)]
    2021-05-02 sunylz

相关资讯

JAMA Netw Open:开放式与机器人辅助根治性前列腺切除术的1年医疗费用和使用情况比较

最近,有研究人员比较了开放式根治性前列腺切除术(ORP)与机器人辅助根治性前列腺切除术(RARP)1年后的医疗费用和使用情况。

Eur Urol Oncol:前列腺活检更佳方法的选择

虽然磁共振成像(MRI)-靶向活检(TBx)相对于系统性活检(SBx)能更好地检测前列腺癌(PCa),但相对于单独的Bx方法,两种方法的结合能提高临床显著PCa的检测。然而,联合Bx要让患者接受更多的

Eur Urol Oncol:68 Ga-前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描和多参数磁共振成像在预测前列腺活检病理方面的联合效用

68镓标记的前列腺特异性膜抗原正电子发射断层扫描(68Ga-PSMA-11 PET)是一种有价值的分期工具,但其在表征原发性前列腺癌方面的效用仍不清楚。最大标准化摄取值(SUVmax)是PET无损伤病

Eur Urol Focus:机器人辅助根治性前列腺切除术后尿失禁的预测

已有研究表明,机器人手术期间记录的器械运动学指标可以预测尿失禁的结果。

盘点:近期前列腺疾病研究进展(五)

前列腺是男性生殖器附属腺中最大的实质性器官。由前列腺组织和肌组织构成。前列腺炎是指由多种复杂原因引起的,以尿道刺激症状和慢性盆腔疼痛为主要临床表现的前列腺疾病。前列腺炎是泌尿外科的常见病,在泌尿外科5

Eur Urol Focus:钬激光和铥激光前列腺切除术:随机对照试验的系统回顾和元分析

钬激光(HoLEP)和铥激光(ThuLEP)是最常用于内窥镜下前列腺切除术的两种方法。目前仍不清楚这两种方法在疗效和并发症方面哪个表现更好。